TD Asset Management Inc. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TD Asset Management Inc. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 359,389 shares of the biopharmaceutical company's stock after acquiring an additional 29,322 shares during the period. TD Asset Management Inc. owned about 0.33% of Regeneron Pharmaceuticals worth $256,004,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of REGN. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the period. Amundi raised its holdings in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock worth $495,639,000 after purchasing an additional 22,538 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock worth $215,562,000 after purchasing an additional 1,108 shares in the last quarter. Finally, Candriam S.C.A. grew its holdings in Regeneron Pharmaceuticals by 3.6% in the fourth quarter. Candriam S.C.A. now owns 261,498 shares of the biopharmaceutical company's stock valued at $186,273,000 after purchasing an additional 8,973 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Regeneron Pharmaceuticals Trading Up 0.2 %

REGN traded up $1.53 during trading hours on Friday, reaching $637.36. The company's stock had a trading volume of 805,912 shares, compared to its average volume of 673,409. The stock has a market cap of $69.68 billion, a PE ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business's 50-day moving average is $683.88 and its 200-day moving average is $797.99.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $11.86 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analyst Ratings Changes

REGN has been the topic of a number of recent analyst reports. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Bank of America reaffirmed an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. Finally, Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.